Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest

This study tests the drug brigatinib in people with a specific type of advanced lung cancer called ALK-positive non-small cell lung cancer. The goal is to see how well the drug controls the cancer and delays its growth. About 118 adults with stage III or IV disease that cannot be…

This study tests whether combining the targeted drug trastuzumab-deruxtecan with other therapies before surgery is safe and effective for people with HER2-positive stomach or esophagus cancer. About 36 adults with locally advanced but removable tumors will receive the drug combin…

This study tests a drug called bemarituzumab combined with different chemotherapies in 126 people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). Participants have already tried at least one prior chemotherapy. The goal is to see if…

This study tests a combination of two drugs, atezolizumab and derazantinib, in 27 adults with advanced bile duct cancer that has a specific change in the FGFR2 gene. The goal is to see if the treatment can shrink tumors and to monitor any side effects. Participants receive the dr…

This study tests a three-drug combination (chemotherapy plus two targeted therapies) as a first treatment for people with a specific type of bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors and improves surviv…

This early-stage study tests an experimental drug called IMP321, which aims to boost the immune system against cancer. It is given alongside standard treatments like chemotherapy or immunotherapy to people with advanced solid tumors that have spread. The main goal is to see if th…

This study tests a new combination of three drugs (rituximab, polatuzumab vedotin, and glofitamab) for people over 60 with aggressive B-cell lymphoma who cannot tolerate standard full-dose chemotherapy. The goal is to see if this milder treatment can control the disease and impro…

This study looks at whether a new combination of drugs (ramucirumab plus FOLFIRI) can help people with advanced stomach or gastroesophageal junction cancer live longer. It is for patients whose cancer got worse after one round of chemotherapy. The trial compares this new combo to…

This study tests whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) to a type of internal radiation therapy (Y-90 SIRT) can shrink tumors in people with advanced bile duct cancer that has not spread beyond the liver. About 50 adults whose cancer cannot be …